ALTG 13/001 TROG 13.01 SAFRON II: Stereotactic Ablative Fractionated Radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the Lung: A Randomised Phase II Trial – S Siva

This trial aims to evaluate single fraction SABR (28Gy/1) versus fractionated SABR (48Gy/4) in a randomised phase II trial of 84 patients. This study aims to assess safety of the two techniques and to compare quality of life outcomes, clinical efficacy and the resource usage and costs associated of each technique. This study also aims to establish a fully annotated trial-related bank of blood and pre-treatment tissue for future analysis.

The study is conducted under the auspices of the Trans Tasman Radiation Oncology Group (TROG) and closed to recruitment 13 June 2018.

Publications

Pham D, Hardcastle N, Foroudi F, Kron T, Bressel M, Hilder B, Chesson B, Oates R, Montgomery R, Ball D, Siva S. A Multidisciplinary Evaluation of a Web-based eLearning Training Programme for SAFRON II (TROG 13.01): A Multicentre Randomised Study of Stereotactic Radiotherapy for Lung Metastases. Clin Oncol. 2016 Sep; 28(9):e101-08.

Siva S, Kron T, Bressel M, Haas M, Mai T, Vinod S, Sasso G, Wong W, Le H, Eade T, Hardcastle N, Chesson B, Pham D, Høyer M, Montgomery R, Ball D. A Randomised Phase II Trial of Stereotactic Ablative Fractionated Radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the Lung (TROG 13.01 SAFRON II). BMC Cancer. 2016 Mar: 16:183

Study Contacts
Trial Chair: Dr Shankar Siva, Peter MacCallum Cancer Centre     shankar.siva@petermac.org
Trial Co-ordinator: Brita Lehmann, TROG Cancer Research     SAFRONII@trog.com.au

Upcoming Events
  1. ALTG open MAC and SAC meetings

    November 20
  2. Virtual 2020 World Conference on Lung Cancer Singapore

    January 28, 2021 @ 8:00 am - January 31, 2021 @ 5:00 pm